HARBIN, China, May 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,
Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading
fully integrated pharmaceutical company in the People's Republic of China
("PRC"), today provided an update on the commercialization plan for the 13 new
products. Based on additional market research and customer feedback, the
Company estimates aggregate incremental 2010 sales of approximately $4 million
from these products.
In March and April, the Company successfully launched the following three products as planned: Oxymetazoline Hydrochloride Nasal Drops for acute and chronic rhinitis, sinusitis and allergic rhinitis; Moschus Liniment for relief of pain from scathe, wound, rheumatism and arthrosis; Ftibamzone Liniment to treating herpes and fungal skin infection.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visithttp://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Advertisement
In March and April, the Company successfully launched the following three products as planned: Oxymetazoline Hydrochloride Nasal Drops for acute and chronic rhinitis, sinusitis and allergic rhinitis; Moschus Liniment for relief of pain from scathe, wound, rheumatism and arthrosis; Ftibamzone Liniment to treating herpes and fungal skin infection.
Advertisement
The remaining ten new products will be launched during the rest of 2010.
Product Name Description Expected Launch
Tobramycin Eye To treat acute infection on eyelids May 2010
Drops
Calcium Folinate An auxiliary therapy for sprue (a May 2010
Injection disease of the small intestine),
malnutrition, pregnancy- or infancy-
related megaloblastic anemia, and
colonic and rectal cancer
Sodium To treat allergic conjunctivitis May 2010
Cromoglicate
Eye Drops
Aciclovir Gel To treat the skin infection due to June 2010
varicella-zoster virus and the herpes
simplex virus
Antiasthma cream To treat cough, asthma and chronic June 2010
bronchitis
Naphazoline For the sterilization and rheum June 2010
Hydrochloride prevention and for the treatment
Chlorpheniramine of rheumatic diseases
Maleate and
Benzalkonium
Bromide Spray
Skincare Cream To treat skin diseases such as acne, July 2010
bottle nose, chromophytosis
and vitiligo
Nasal Drop To treat the snuffle August 2010
Propylgallate To treat cerebro-vascular infarction, August 2010
for Injection angina, hypertention and coronary
heart diseases
Dithranol to treat different types of September 2010
ointment psoriasis, such as plaque psoriasis,
guttate psoriasis and hypertrophy
psoriasis;
"We look forward to the commercial launch of the remaining ten new
products in 2010. China Sky One remains committed to the research and
development of new products to create more growth opportunities in the
long-term," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visithttp://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the production timeline and its effect on the Company's operational results. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, achievability of management's estimates of product sales, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For further information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-0451-8703-2617
Email: [email protected]
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: [email protected]
Web: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: [email protected]
SOURCE China Sky One Medical, Inc.